Send to

Choose Destination
JACC Cardiovasc Interv. 2016 Jun 27;9(12):1231-42. doi: 10.1016/j.jcin.2016.03.027. Epub 2016 Jun 1.

The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.

Author information

ThoraxCenter, Erasmus University Medical Center, Rotterdam, the Netherlands; Academic Medical Center, Amsterdam, the Netherlands; Northern Region Heart Center, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Academic Medical Center, Amsterdam, the Netherlands.
ThoraxCenter, Erasmus University Medical Center, Rotterdam, the Netherlands.
Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York.
Hospital Universitario Clínico San Carlos, Madrid, Spain.
Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
King's College Hospital, London, England.
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Freeman Hospital, Newcastle upon Tyne, England.
Department of Cardiology, Pasteur Hospital, Toulouse, France.
1st Department of Cardiology, Medical University of Poznan, Poland.
Institut Jacques Cartier, Massy, France.
International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, England. Electronic address:



The study sought to investigate the relationship between post-procedural asymmetry, expansion, and eccentricity indices of metallic everolimus-eluting stent (EES) and bioresorbable vascular scaffold (BVS) and their respective impact on clinical events at 1-year follow-up.


Mechanical properties of a fully BVS are inherently different from those of permanent metallic stent.


The ABSORB II (A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions) trial compared the BVS and metallic EES in the treatment of a de novo coronary artery stenosis. Protocol-mandated intravascular ultrasound imaging was performed pre- and post-procedure in 470 patients (162 metallic EES and 308 BVS). Asymmetry index (AI) was calculated per lesion as: (1 - minimum scaffold/stent diameter/maximum scaffold/stent diameter). Expansion index and optimal scaffold/stent expansion followed the definition of the MUSIC (Multicenter Ultrasound Stenting in Coronaries) study. Eccentricity index (EI) was calculated as the ratio of minimum and maximum scaffold/stent diameter per cross section. The incidence of device-oriented composite endpoint (DoCE) was collected.


Post-procedure, the metallic EES group was more symmetric and concentric than the BVS group. Only 8.0% of the BVS arm and 20.0% of the metallic EES arm achieved optimal scaffold/stent expansion (p < 0.001). At 1 year, there was no difference in the DoCE between both devices (BVS 5.2% vs. EES 3.1%; p = 0.29). Post-procedural devices asymmetry and eccentricity were related to higher event rates while there was no relevance to the expansion status. Subsequent multivariate analysis identified that post-procedural AI >0.30 is an independent predictor of DoCE (hazard ratio: 3.43; 95% confidence interval: 1.08 to 10.92; p = 0.037).


BVS implantation is more frequently associated with post-procedural asymmetric and eccentric morphology compared to metallic EES. Post-procedural devices asymmetry were independently associated with DoCE following percutaneous coronary intervention. However, this approach should be viewed as hypothesis generating due to low event rates. (ABSORB II Randomized Controlled Trial [ABSORB II]; NCT01425281).


asymmetry; bioresorbable vascular scaffolds; eccentricity; expansion

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center